## Empiric Coverage for Surgical Site Infection **Key Point:** In a clean-contaminated procedure (biliary surgery) with suspected SSI, empiric broad-spectrum coverage is required because the infecting organism is unknown at presentation and may include both gram-positive and gram-negative pathogens. ### Rationale for Ceftriaxone Ceftriaxone is a **third-generation cephalosporin** with: - Excellent coverage of gram-negative organisms (E. coli, Klebsiella, Proteus) - Adequate gram-positive coverage (Staphylococcus aureus, Streptococcus) - Superior tissue penetration and half-life compared to first-generation agents - Anaerobic coverage when combined with metronidazole (if indicated) **High-Yield:** For clean-contaminated SSI (GI, biliary, gynecologic surgery), third-generation cephalosporins are preferred over first-generation agents because they provide broader gram-negative coverage, which is critical in biliary tract infections where enteric organisms predominate. ### Comparison with Alternatives | Agent | Spectrum | Use in SSI | |-------|----------|----------| | **Ceftriaxone** | Gram-neg >> gram-pos, anaerobes (with metro) | **First-line for clean-contaminated SSI** | | Cefazolin | Gram-pos > gram-neg, poor anaerobic | Prophylaxis only; inadequate for established SSI | | Vancomycin | Gram-pos only, MRSA coverage | Reserved for MRSA risk or beta-lactam allergy | | Fluoroquinolone | Gram-neg > gram-pos, no anaerobic | Monotherapy insufficient; adjunct only | **Clinical Pearl:** Once culture and sensitivity results are available (typically 48–72 hours), therapy should be de-escalated to the narrowest effective agent to reduce antibiotic resistance and adverse effects. **Warning:** Cefazolin, though used for prophylaxis in clean surgery, is inadequate for treatment of established SSI because it is a first-generation agent with limited gram-negative coverage—a critical gap in biliary infections where E. coli is common.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.